A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol inclusion/exclusion criteria may apply
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
Zhejiang, Zhejiang 310022, China
Lyon Cedex08, Auvergne-Rhône-Alpes 69373, France
Ota-shi, Gunma 3738550, Japan
Akashi-shi, Hyōgo 6738558, Japan
Himeji-shi, Hyōgo 6708520, Japan
Shiwa-gun, Iwate 0283695, Japan
Habikino-shi, Osaka 5838588, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Ube-shi, Yamaguchi 7550241, Japan
Veracruz, Veracruz, 91900, Mexico
Tauton, TA1 5DA, United Kingdom